1.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GS-US-312-0117, NCT01539291
|
|
2.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GS-US-312-0116, NCT01539512
|
|
3.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GS-US-312-0115, NCT01569295
|
|
4.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GS-US-312-0119, NCT01659021
|
|
5.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 101-10, NCT01306643
|
|
6.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 101-09, 2010-022155-33, NCT01282424
|
|
7.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 12 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 101-11, NCT01393106
|
|
8.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 101-07, NCT01088048
|
|
9.
|
Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 101-99, NCT01090414
|
|
10.
|
Phase: Phase I Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-A051202, A051202, NCT01644799
|